Colorectal Cancer Screening and Diagnostics: Introduction
- Given the rising incidence of colorectal cancer globally, the market for colorectal cancer screening is anticipated to expand significantly. Improvements in screening technology and growing awareness of the importance of routine screening are also anticipated to propel market expansion. The market is growing as a result of favorable government programs and reimbursement practices that encourage the use of colorectal cancer screening. Growing emphasis on colorectal cancer’s early detection can hence increase demand for screening tests.
- Colorectal cancer ranks third among cancer-related causes of mortality for both - men and women in the United States.
- The American Cancer Society had estimates that 52,580 people succumbed to cancer in the United States in 2022, while 106,180 new cases were diagnosed.
Increasing Demand for Colorectal Cancer Screening Tests.
- The expansion of the global colorectal cancer screening and diagnostics market is anticipated to be driven by rising demand for these tests over the forecast period. For example, the Guardant Health, Inc. introduced Shield, their first blood-based test for detecting colorectal cancer in its early stages, in May 2022. Adults over 45 who are at average risk of colorectal cancer do not exhibit any symptoms, and are not following suggested screening standards are the target audience for the test.
- The market for colorectal cancer screening and diagnostics is expanding due to the rising demand for colorectal cancer (CRC) screening tests. One of the most common malignancies in the world is colorectal cancer, and lowering death rates depends heavily on early identification. More people are choosing routine screening tests as a result of government-sponsored programs, enhanced screening technology, and growing knowledge of the advantages of early detection. By raising the demand for sophisticated diagnostic equipment, laboratory services, and creative screening techniques, this rising demand directly supports market growth.
Government Initiatives and Policies Associated with Cancer Screening Tests expected to Drive Overall Colorectal Cancer Screening and Diagnostics Market
- In an effort to lower the incidence of colorectal cancer worldwide, governments in a number of nations have strengthened their screening regulations. Governments in numerous nations have implemented measures such as routine screening programs for those who are susceptible to contracting the disease, in an effort to reduce the growing incidence of colorectal cancer.
- These programs provide low-cost CRC detection. They are among the main causes of the rise in screening procedures carried out worldwide, particularly in industrialized nations like the United States, South Korea, and the United Kingdom.
- For instance, as per data published by BioMed Central Ltd, in 2021, the National Cancer Screening Program (NCSP) offers CRC screening at no cost in the Republic of Korea.
- Moreover, in July 2024, Guardant Health, Inc., a leading precision oncology company, announced the U.S. Food and Drug Administration (FDA) approved the company’s Shield blood test for colorectal cancer (CRC) screening in adults aged 45 and older who are at average risk of the disease. It is the first blood test to be approved by the FDA as a primary screening option for CRC, meaning healthcare providers can offer Shield in a manner similar to all the other non-invasive methods recommended in screening guidelines.
Increasing Incidence of Colorectal Cancer to Boost the colorectal cancer screening and diagnostics market Growth
- Colorectal cancer incidence in the U.S. is the highest in people who are Alaska Native (88.5 per 100,000), American Indian (46.0), or Black (41.7) versus White (35.7); racial and ethnic disparities are similar for mortality. Moreover, according to data from the 2020 Behavioral Risk Factor Surveillance System, up-to-date screening prevalence among adults 45 years, and older ranged from 53% in California to 70% in Massachusetts and the District of Columbia
By Test Type, the Colonoscopy segment accounted for the largest share of the colorectal cancer screening and diagnostics industry
- The colorectal cancer screening and diagnostics market is divided into Stool DNA Test, Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), Colonoscopy, Sigmoidoscopy, and others based on test type. The market for colorectal cancer screening and diagnostics was dominated by the Colonoscopy category in 2024 under the test type market segment.
- The second leading cause of cancer-related fatalities globally is colorectal cancer. Studies show that screening for colorectal cancer reduces the disease's chance of death. The two most commonly used screening tests are fecal testing and colonoscopy, which entails putting a small camera into the digestive tract.
- For instance, a team of researchers recruited 84,585 men and women between the ages of 55 and 64 who had never had a colorectal cancer screening, according to data published in the New England Journal of Medicine in October 2022. Following the removal of the polyps, the researchers observed that 15 patients suffered from significant bleeding. Nevertheless, within 30 days following the colonoscopy, there were no perforations or screening-related fatalities.
These are some of the factors expected to dominate colonoscopy segment in the overall test type market segment.
North America to Lead the Colorectal Cancer Screening and Diagnostics Market
- With an anticipated 37.9% market share in 2025, North America continues to dominate the worldwide colorectal cancer screening market. Leading biotechnology and medical device manufacturers in the United States have made it possible for cutting-edge technical advancement. Regular screening has become standard practice for the population over 50 due to strict screening criteria set by organizations like the United States Preventive Services Task Force.
- The market for colorectal cancer screening is expected to develop at the quickest rate in Asia Pacific. The market is expanding due to rising healthcare costs and better access to healthcare in nations like China, India, and Japan. The region's economic expansion has made high-quality cancer treatment more affordable. Additionally, governments are implementing preventive measures in response to the increasing prevalence of colorectal cancer brought on by lifestyle changes and the adoption of a western diet. For example, India has started a number of public awareness initiatives to encourage colorectal cancer screening.
Key Players Operating in Global Colorectal Cancer Screening and Diagnostics Market
The major players operating in the global market are focusing on advancements in research and development to meet the rising demand for colorectal cancer screening and diagnostics solutions. Moreover, service providers are entering into partnerships for the development of innovative products.
Key players operating in the global colorectal cancer screening and diagnostics market include:
- Polymedco Inc.
- Eiken Chemical Co. Ltd.
- Sysmex Corporation
- Siemens Healthineers AG
- Quidel Corporation
- Novigenix SA
- Hemosure Inc.
- Exact Sciences Corp.
- Epigenomics Inc.
- Olympus Corporation
- Clinical Genomics Technologies Pty Ltd.
- Exact Sciences Corporation
- Other Prominent Players
Market Segmentation :
- By Product Type:
- Instruments
- Reagents & Kits
- By Test Type:
- Stool DNA Test
- Fecal Immunochemical Test (FIT)
- Fecal Occult Blood Test (FOBT)
- Colonoscopy
- Sigmoidoscopy
- Others (Double-contrast barium enema, Blood Tests, etc.)
- By End-user:
- Clinical Laboratories
- Diagnostic Imaging Centers
- Hospitals & Clinics
- By Region:
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
